Skip to main content
Premium Trial:

Request an Annual Quote

America's Choice Provider Network to Cover CombiMatrix's Molecular Dx Testing Services

NEW YORK (GenomeWeb News) – America's Choice Provider Network will now cover CombiMatrix's diagnostic laboratory services, CombiMatrix said today.

ACPN is a San Diego-based company that facilitates out-of-network services for more than 540 payers in the US, reaching about 14 million people. Under the new agreement, individuals whose healthcare providers liaise with ACPN will now have access to CombiMatrix's menu of chromosomal microarray-based prenatal, pediatric, and cancer cytogenetic testing services.

In addition to CMA, Irvine, Calif.-based CombiMatrix also offers fluorescence in situ hybridization, PCR and G-band chromosome analyses.

The firm, which saw its third quarter revenues rise 15 percent on increased prenatal testing volumes, has announced a number of payor agreements this year. Earlier this month, it announced a deal with Blue Cross and Blue Shield of Kansas City. In October, CombiMatrix said it had reached a deal with Three Rivers Provider Network, and during the summer it inked an agreement with Blue Shield of California.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.